BioSpace News Archive

Bristol Myers Squibb announced an update on the Phase 3 CheckMate -651 trial comparing Opdivo plus Yervoy to the EXTREME regimen as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.

Avantor, Inc. today announced that it has changed the date of its previously announced earnings release and conference call. The Company will now release its financial results for the second quarter 2021 after the market closes on Thursday, July 29, 2021, and will hold a conference call on Friday, July 30, 2021 to discuss the results at 7:30 a.m. Eastern Daylight Time.

Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting i

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon ranked 16th out of 100 large companies.

TempraMed is creating easy to use, hassle free solutions that save patients lives by protecting them from damaged medications.

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

PharmEnable announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against coronaviruses.

Two INDs were submitted to the FDA in May 2021 for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors.

Aurinia Pharmaceuticals Inc., a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange effective as of the close of trading on July 30, 2021.